Today: 7 February 2026
Subscribe
Browse Category

Biotech News News 5 January 2026 - 9 January 2026

Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

New York, Jan 9, 2026, 14:36 (EST) — Regular session Nuvation Bio Inc (NUVB) shares slid about 4.7% to $8.05 Friday afternoon, after earlier hitting a session low of $8.05. The stock’s pullback follows new sell-side takes on a name that’s been re-rated since shifting into the commercial stage. UBS started coverage at Neutral with a $10 price target. RBC, meanwhile, lifted its target to $9 from $8 and maintained an Outperform rating, calling the stock “speculative risk.” (MarketScreener) UBS analyst Michael Yee said the bigger picture is starting to turn, arguing biotech “fundamentals are now inflecting” as investor confidence
9 January 2026
···
Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

New York, January 8, 2026, 14:40 EST — Regular session Arcus Biosciences (RCUS) shares slid 9.3% to $21.05 in afternoon trading on Thursday, after earlier touching $22.70. The stock hit a session low of $21.02. Morgan Stanley cut its rating on Arcus to “equal weight” from “overweight” and trimmed its price target to $20 from $23, Investing.com reported, calling the risk-reward more balanced after a strong 2025 run. The Nasdaq Biotechnology Index was down about 2.8%. Investing.com Arcus laid out its 2026 playbook late Wednesday, keeping casdatifan — which it has billed as a potential best-in-class HIF-2a inhibitor, a protein
8 January 2026
·····
Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

NEW YORK, Jan 8, 2026, 08:59 (EST) — Premarket Omeros Corp (OMER.O) shares were up 0.55, or about 4%, at $14.09 in premarket trade on Thursday after the drugmaker set a $36,000 price for each single-dose vial of its newly approved Yartemlea treatment for transplant-associated thrombotic microangiopathy (TA-TMA). “Median utilization was 8 to 10 vials per treatment course,” Chief Executive Gregory Demopulos told analysts. The stock rose 6.6% in extended trade on Wednesday. Reuters The pricing matters because Omeros is trying to turn a long-running development story into a launch, with Yartemlea (narsoplimab-wuug) positioned as the first and only approved
8 January 2026
·····
Legend Biotech (LEGN) stock jumps after Oppenheimer starts coverage with $75 target

Legend Biotech (LEGN) stock jumps after Oppenheimer starts coverage with $75 target

New York, January 7, 2026, 12:32 (EST) — Regular session Shares of Legend Biotech Corp rose 7.4% to $22.53 in midday trading on Wednesday after Oppenheimer initiated coverage with an “Outperform” rating and set a $75 price target, according to MarketBeat. StreetInsider said Oppenheimer analyst Trevor Allred authored the initiation note. MarketBeat Why it matters now: Legend’s stock has been under pressure and touched a 52-week low of $21.16 earlier this week, keeping investors sensitive to any shift in the narrative around its lead product, Carvykti. Carvykti is a CAR‑T therapy — a personalized cancer treatment that uses a patient’s
7 January 2026
·····
Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next

Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next

New York, Jan 7, 2026, 11:10 EST — Regular session Shares of Abivax SA jumped 7.3% to $127.75 in morning trading on Wednesday, after touching a session high of $128.87 and a low of $119.48. Trading volume topped 700,000 shares. The French biotech’s U.S.-listed stock has become a fast-moving name for healthcare traders, in part because its valuation rests on a single late-stage drug program. Its American depositary shares, or ADSs, are U.S.-traded certificates that represent ownership of a foreign company’s shares. Abivax is developing obefazimod, an oral treatment candidate for ulcerative colitis, a chronic inflammatory bowel disease. The company
7 January 2026
·····
Ventyx Biosciences stock jumps premarket as Eli Lilly buyout talks fuel takeover buzz

Ventyx Biosciences stock jumps premarket as Eli Lilly buyout talks fuel takeover buzz

New York, Jan 7, 2026, 05:03 EST — Premarket Ventyx Biosciences shares jumped about 66% before the bell on Wednesday after a report that Eli Lilly is in advanced talks to buy the biotech company for more than $1 billion. The stock traded at $16.70 in premarket action, versus a $10.05 regular-session close. Public The move matters because a confirmed deal would lock in a takeover premium for a company whose value has swung sharply on trial timelines and pipeline expectations. It also tests whether big drugmakers are willing to pay up for clinical-stage assets tied to inflammation and obesity-linked
7 January 2026
······
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

New York, January 6, 2026, 15:27 (ET) — Regular session Nasdaq-listed Travere Therapeutics shares fell 5.3% to $36.09 in afternoon trading on Tuesday as investors looked toward next week’s U.S. FDA decision deadline on expanding its kidney drug Filspari (sparsentan) into focal segmental glomerulosclerosis. The FDA’s Prescription Drug User Fee Act, or PDUFA, target action date is Jan. 13, and the stock has ranged from $34.88 to $39.16 in the session. SEC The case matters for Travere because FSGS is a rare disease that scars the kidney’s filtering units and can progress to kidney failure. An added label would broaden
6 January 2026
·····
Johnson & Johnson stock ticks up on lupus drug data as earnings loom

Johnson & Johnson stock ticks up on lupus drug data as earnings loom

New York, January 6, 2026, 12:58 EST — Regular session Johnson & Johnson (JNJ.N) shares rose on Tuesday after the company reported positive mid-stage data for its experimental lupus drug nipocalimab and outlined plans for late-stage testing. The stock was up $1.10, or 0.5%, at $205.41 in midday New York trading. The update puts fresh focus on J&J’s drug pipeline at a time investors are leaning on healthcare for steadier earnings and dividends. New medicines are also a key lever for the company as it looks to offset slower growth in mature brands and keep pricing power in its core
6 January 2026
·····
Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update

Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update

NEW YORK, Jan 5, 2026, 15:54 EST — Regular session Shares of Immunome, Inc. fell 5.3% to $19.72 in late afternoon trading on Monday, underperforming U.S. biotech peers. The SPDR S&P Biotech ETF slid 1.1% and the iShares Nasdaq Biotechnology ETF was off 0.9%. IMNM opened at $20.83 and touched $19.36, with about 1.6 million shares changing hands by 3:54 p.m. EST, according to market data. Immunome has not posted a news release since Dec. 16, when it priced a public offering of common stock, the company’s investor relations site showed. That quiet calendar can magnify day-to-day swings in small-cap
5 January 2026
·····
Argenx stock slides 5% on CEO handover plan — what investors watch next

Argenx stock slides 5% on CEO handover plan — what investors watch next

New York, Jan 5, 2026, 15:30 EST — Regular session Shares of argenx fell about 5% on Monday after the immunology drugmaker said Chief Operating Officer Karen Massey will succeed co-founder Tim Van Hauwermeiren as CEO, with Van Hauwermeiren set to become board chairman pending a shareholder vote on May 6. The stock was down 5% at $797.94 in afternoon trading. argenx The CEO handover matters because argenx is priced like a growth company that still has to prove it can widen its flagship franchise while keeping a costly pipeline on track. Any hint of a change in risk appetite
5 January 2026
····
Spyre Therapeutics stock drops as biotech slides — what SYRE investors watch next

Spyre Therapeutics stock drops as biotech slides — what SYRE investors watch next

New York, January 5, 2026, 15:09 EST — Regular session Shares of Spyre Therapeutics Inc fell 2.7% to $29.75 in afternoon trading on Monday, extending a choppy start to the year for smaller biotechnology names. The stock traded between $28.02 and $30.75, with about 0.63 million shares changing hands. The decline tracked weakness across the biotech complex, with the SPDR S&P Biotech ETF down 1.7% and the iShares Nasdaq Biotechnology ETF off 1.5%. Both are exchange-traded funds, meaning baskets of stocks that trade like a single share, while the SPDR S&P 500 ETF rose 0.7%, underscoring the sector’s underperformance. That
5 January 2026
····
Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

New York, January 5, 2026, 1:09 PM ET — Regular session Wave Life Sciences Ltd shares fell $1.34, or 8.4%, to $14.61 in afternoon trade on Monday, extending a sharp pullback in the clinical-stage biotech even as the company flagged an investor-conference appearance next week. The move matters because the J.P. Morgan Healthcare Conference often sets the tone for biotech investing early in the year, and Wave’s stock has become closely tethered to expectations for updates on its obesity program and financing needs. Biotech lagged more broadly, with the SPDR S&P Biotech ETF down about 2.1% and the iShares Nasdaq
5 January 2026
····
1 2 3 4 5 6 … 12

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop